Anavex Life Sciences Corp (AVXL)

[falconer66a]

Important correction.

I just got a private message from a frequent, very helpful board member. I appreciate his message to me. VERY important (and accurate).

He notes that I made this claim: "As noted previously, blarcamesine, against Alzheimer’s, is effective in about 80% of those with the disease."

But here’s the correction:

According to TGD [the good doctor, CEO Christopher Missling], A2-73 is effective in pretty much everyone - not just 80% of those with AD.

As I recall, he compared the effectiveness of those with the wild type protein (i.e. the 80%) as taking an elevator to the top floor of a building. And those without the wild type (i.e. the remaining 20% of the population) as having to take the stairs...it's still effective for them, it would just take a little longer for them to get to the top floor. (I'm paraphrasing, of course)

Yes! Thank you; a point I failed to make. For a fraction, about 20% of those with Alzheimer’s, blarcamesine does not work as well. It will take either/or longer for it to take effect, or larger doses.

I’m betting that for people with unfavorable blarcamesine genetics, dosages will have to be carefully titrated (slow, small incremental dosage increases) to the level of efficacy. This probably will take time, many weeks or months. But, in the end, symptomatic relief, at least to some degree, will be attained. Getting there will take greater time and effort. Success, nonetheless.

Then, of course, next will be the question of Anavex 3-71. Will it work for everyone, or will it, too, need titrated dosage increases for some?

Again, for the poster who sent me the private message, thanks. Blarcamesine is better than I portrayed it; will help almost everyone with Alzheimer’s; but may take longer for some, with carefully titrated dose increases. Far better than anything available now for Alzheimer’s.